Selected outcomes in 2019

During working and utilization of our large research infrastructure BBMRI.cz were created plenty of unique outcomes. Here we mention some of them:

Bencsiková, B., Budinská, E., Selingerová, I., Pilátová, K., Fědorová, Lakomy, R.,, L., Greplová, K., Nenutil, R., Valík, D., Obermannová, R., Sheard, M.A., Zdražilová Dubská, L. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness. BMC Cancer 2019;19(1):687. doi: 10.1186/s12885-019-5909-5. (IF2018: 2,933)
Fucikova, J., Rakova, J., Hensler, M., Kasikova, L., Belicova, L., Hladikova, K., Truxova, I., Skapa, P., Laco, J., Pecen, L., Praznovec, I., Halaska, M.J., Brtnicky, T., Kodet, R., Fialova, A., Pineau, J., Gey, A., Tartour, E., Ryska, A., Galluzzi, L., Spisek, R. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clin Cancer Res 2019;25(15):4820-4831. doi: 10.1158/1078-0432.CCR-18-4175. (IF2018: 8,911; Q1)
Gómez-Herranz, M., Nekulová, M., Faktor, J., Hernychová, L., Kote, S., Sinclair, E.H., Nenutil, R., Vojtěšek, B., Ball, K.B., Hupp, T.R. The effects of IFITM1 and IFITM3 gene deletion on IFNγ stimulated protein synthesis. Cell Signal 2019;60:39-56. doi: 10.1016/j.cellsig.2019.03.024. (IF2018: 3,388)
Hladíková, K., Koucký,, Bouček, J., Laco, J., Grega, M., Hodek, M., Zábrodský, M., Vošmik, M., Rozkošová, K., Vošmiková, H., Čelakovský, P., Chrobok, V., Ryška, A., Špíšek, R., Fialová, A. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+) T cells. J Immunother Cancer 2019;7(1):261. doi: 10.1186/s40425-019-0726-6. (IF2018: 8,676; Q1)
Jiraskova, L., Ryska, A., Duintjer, Tebbens, E.J., Hornychova, H., Cecka, F., Staud, F., Cerveny, L. Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy? Cancers (Basel) 2019;11(11):1621. doi: 10.3390/cancers11111621. (IF2018: 6,162; Q1)
Kasikova, L., Hensler, M., Truxova, I., Skapa, P., Laco, J., Belicova, L., Praznovec, I., Vosahlikova, S., Halaska, M.J., Brtnicky, T., Rob, L., Presl, J., Kostun, J., Cremer, I., Ryska, A., Kroemer, G., Galluzzi, L., Spisek, R., Fucikova, J. Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. J Immunother Cancer 2019;7(1):312. doi: 10.1186/s40425-019-0781-z. (IF2018: 8,676; Q1)
Kyr, M., Polášková, K., Kuttnerová, Z., Merta, T., Neradil, J., Berkovcová, J., Ježová, M., Veselská, R., Lakka Klement, G., Valík, D., Štěrba, J. Individualization of Treatment Improves the Survival of Children With High-Risk Solid Tumors: Comparative Patient Series Analysis in a Real-Life Scenario. Front Oncol 2019;9(July 2019):644. doi: 10.3389/fonc.2019.00644. (IF2018: 4,416)
Němejcová, K., Tichá, I., Bártů, M., Kodet, O., Důra, M., Jakša, R., Michálková, R., Dundr, P. Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma. Pigment Cell Melanoma Res 2019;32(3):412-423. doi: 10.1111/pcmr.12757. (IF2018: 4,172)
Ticha, I., Hojny, J., Michalkova, R., Kodet, O., Krkavcova, E., Hajkova, N., Nemejcova, K., Bartu, M., Jaksa, R., Dura, M., Kanwal, M., Martinikova, A.S., Macurek, L., Zemankova, P., Kleibl, Z., Dundr, P. A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. Sci Rep 2019;9(1):17050. doi: 10.1038/s41598-019-53636-x. (IF2018: 4,011)
Vyskočil, J., Tuček, Š., Kiss, I., Fědorová, L., Nevrlka, J., Zdražilová Dubská, L. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening. Int Immunopharmacol 2019;2019(74):105728. doi: 10.1016/j.intimp.2019.105728. (IF2018: 3,361)